CanSino Biologics (HKG:6185, SHA:688185) narrowed its attributable loss in the first quarter to 11.5 million yuan from 170.1 million yuan in the year-ago period, a Tuesday Hong Kong bourse filing said.
Loss per share stood at 0.05 yuan, down from 0.69 yuan in the same period of the last fiscal year.
The vaccine manufacturer saw its operating revenue for the three months rise by 20% to 137.2 million yuan from 114.3 million yuan a year prior.
The firm attributed the lower loss mainly to an increase in operating revenue amid a rising market share of its vaccine product Menhycia in China, a rise in other income due to government grants and international funding support, and reduced spillover costs.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.